On April 21, 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) Program just released (Press release, Veracyte, APR 21, 2025, View Source [SID1234651996]). This database will enable eligible researchers to evaluate Decipher Prostate test results in the context of real-world patient outcomes, prostate cancer characteristics, treatment protocols, demographics and other factors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited about the numerous opportunities that our collaboration with the NCI SEER Program will enable for prostate cancer researchers and, ultimately, for patients," said Philip Febbo, M.D., Veracyte’s chief scientific officer and chief medical officer. "It also reinforces Veracyte’s commitment to building clinical evidence for our tests and to advancing scientific understanding of cancer and its biological underpinnings."
The NCI SEER Program is an authoritative source of population-based information on cancer incidence and survival in the United States. The SEER specialized database containing de-identified Decipher Prostate Genomic Classifier data is based on a linkage conducted by the SEER registries and included over 560,000 prostate cancer cases diagnosed from 2010 to 2018. The Decipher Prostate test has been available for use on radical prostatectomy specimens since 2013 and on biopsy tissue since 2016.
About Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test’s performance and clinical utility has been demonstrated in over 85 studies involving more than 200,000 patients. It is the only gene expression test to achieve "Level I" evidence status and inclusion in the risk-stratification table in the most recent NCCN Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.